Illumina, Inc. (ILMN) - Medical Equipment - Deals and Alliances Profile

Date: July 21, 2016
Pages: 116
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I879A39D9EEEN
Leaflet:

Download PDF Leaflet

Illumina, Inc. (ILMN) - Medical Equipment - Deals and Alliances Profile
Summary

Illumina, Inc. (Illumina) provides sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and oncology. The company’s portfolio encompasses sequencing tools and systems; sequencing kits and reagents; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina caters its services to pharmaceutical companies, genomic research centers, academic institutions, biotechnology companies and clinical research organizations. The company's products are distributed to various countries through its distributors in Africa, Asia Pacific, Central America, Europe, the Middle East, North America, and South America. Illumina is headquartered in San Diego, California, the US.

Illumina, Inc. (ILMN) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion/divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Illumina, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Illumina, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deal Details
Venture Financing
Human Longevity Raises USD220 Million in Series B Financing Round
Grail Bio Raises USD100 Million in Series A Financing
Oxford Nanopore Raises US$64 Million In Venture Financing
GenoLogics Life Sciences Software Secures US$8 Million In Venture Financing
Genologics Life Sciences Secures US$5.1 Million In Series D Venture Financing
Oxford Nanopore Technologies Raises US$41 Million In Financing Round
Oxford Nanopore Technologies Raises US$28 Million In Financing Round
Partnerships
Illumina Enters Into Licensing Agreement With Quest Diagnostics
Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS
MolecularMD Enters into Agreement with Illumina
ArcherDX Enters into Co-Development Agreement with Illumina
Genomics England Partners with Illumina
Bio-Rad Laboratories Enters into Partnership with Illumina
Novogene Enters into Co-Development Agreement with Illumina
Almac Diagnostics Enters into Agreement with Illumina
Asuragen to Enter into Agreement with Illumina
Illumina Enters into Co-Development Agreement with Annoroad Gene Technology
Merck Serono Enters into Co- Development Agreement with Illumina
Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT
BioMerieux Enters into Co-Development Agreement with Illumina
Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit
HTG Molecular Diagnostics Enters into Agreement with Illumina to Develop IVD Kits for Sequencing Tests
Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test
Pathogenica Enters Into Co-Marketing Agreement With Illumina
Oxford Nanopore To Terminate Co-Marketing Agreement With Illumina
Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics
SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers
Illumina Enters Into Technology Integration Agreement With Partners HealthCare System
Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center
Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina
Olerup SSP Enters Into Distribution Agreement With Conexio Genomics
Covaris Enters Into Co-Marketing Agreement With Illumina
Equity Offering
Desktop Genetics Raises Funds in Equity Investment
Debt Offering
Illumina Raises USD550 Million in Private Placement of Notes Due 2019
Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021
Illumina Completes Private Placement Of 0.25% Convertible Senior Notes Due 2016 For US$800 Million
Asset Transactions
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina
Pathway Genomics Acquires MiSeqDx From Illumina
Novogene Acquires HiSeq X Ten Sequencing System From Illumina
Ambry Genetics Acquires HiSeq 2000 From Illumina
Acquisition
Illumina Acquires Conexio Genomics
Illumina Acquires GenoLogics Life Sciences
Illumina Acquires Myraqa, In-Vitro Diagnostics Company
Illumina Acquires NextBio, Clinical and Genomic Informatics Company
Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For US$91 Million
Illumina Acquires Advanced Liquid Logic
Illumina Completes Acquisition Of Verinata Health, In-Vitro Diagnostics Company, For Up To US$450 Million
Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer
Roche Terminates Plans To Acquire Illumina
Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions
Illumina Acquires Epicentre Biotechnologies
Illumina Acquires Helixis
Illumina, Inc. - Key Competitors
Key Employees
Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Strategy And Business Planning
Oct 28, 2015: BNBuilders Begins Construction on the Illumina San Diego Facility Expansion
Mar 10, 2015: EMD Serono Announces Strategic Collaboration with Illumina for Diagnostics in Oncology
Financial Announcements
May 03, 2016: Illumina Reports Financial Results for First Quarter of Fiscal Year 2016
Apr 18, 2016: Illumina Announces Preliminary Revenue for First Quarter of Fiscal Year 2016
Feb 02, 2016: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2015
Oct 20, 2015: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2015
Jul 21, 2015: Illumina Reports Financial Results for Second Quarter of Fiscal Year 2015
Apr 21, 2015: Illumina Reports Strong Start to Fiscal Year 2015
Jan 27, 2015: Illumina Reports Record Financial Results for Fourth Quarter and Fiscal Year 2014
Corporate Communications
Jun 02, 2016: Illumina Appoints Paula Dowdy Senior Vice President and General Manager of Commercial Operations for Europe, the Middle East and Africa
Mar 07, 2016: Jay Flatley to Assume Role of Executive Chairman of the Board of Directors of Illumina; Francis deSouza Appointed President and CEO
Jan 28, 2016: Illumina Appoints Dr. Frances Arnold to Its Board of Directors
Jul 20, 2015: Illumina Names Sanjay Chikarmane as Senior Vice President and General Manager of Enterprise Informatics
Legal and Regulatory
Jul 04, 2016: Premaitha Health: Progress on anti-trust objections to litigation
Feb 23, 2016: Illumina Sues Oxford Nanopore for Patent Infringement
Jan 07, 2016: Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT
Product News
Feb 24, 2016: Illumina Applies CE Mark to VeriSeq NIPT Analysis Software
Apr 21, 2015: Cloud Health Launches Full Service Capacity of the Illumina HiSeq X Ten Sequencing System
Mar 03, 2015: Genome Analysis of Cancer Cells: Germany’s Biggest Sequencing Unit Established in Heidelberg
Feb 08, 2015: Hamilton Company Partners with Illumina to Automate Process and Library Tracking
Other Significant Developments
Jun 30, 2016: Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance
Jun 16, 2016: Illumina Announces Initial Customer Orders for the Global Screening Array
Jun 06, 2016: ArcherDX Partners with Illumina to Bring Leading Fusion Oncology Assays to Global Markets
Dec 14, 2015: bioMerieux and Illumina announce the launch of bioMerieux EpiSeq, a revolutionary Next-Generation Sequencing service for epidemiological monitoring of bacterial infections
Oct 01, 2015: Illumina Expands World’s Largest Genomics Analysis Platform and Adds to Open Source Initiative
Jun 02, 2015: Illumina Names Pensabio as New Distributor for Brazil
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Illumina, Inc., Medical Equipment, Key Facts, 2015
Illumina, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Illumina, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Illumina, Inc., Deals By Market, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016
Human Longevity Raises USD220 Million in Series B Financing Round
Grail Bio Raises USD100 Million in Series A Financing
Oxford Nanopore Raises US$64 Million In Venture Financing
GenoLogics Life Sciences Software Secures US$8 Million In Venture Financing
Genologics Life Sciences Secures US$5.1 Million In Series D Venture Financing
Oxford Nanopore Technologies Raises US$41 Million In Financing Round
Oxford Nanopore Technologies Raises US$28 Million In Financing Round
Illumina Enters Into Licensing Agreement With Quest Diagnostics
Peter MacCallum Cancer Centre Enters Into Licensing Agreement With GenoLogics Life Sciences Software For Clarity LIMS
MolecularMD Enters into Agreement with Illumina
ArcherDX Enters into Co-Development Agreement with Illumina
Genomics England Partners with Illumina
Bio-Rad Laboratories Enters into Partnership with Illumina
Novogene Enters into Co-Development Agreement with Illumina
Almac Diagnostics Enters into Agreement with Illumina
Asuragen to Enter into Agreement with Illumina
Illumina Enters into Co-Development Agreement with Annoroad Gene Technology
Merck Serono Enters into Co- Development Agreement with Illumina
Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT
BioMerieux Enters into Co-Development Agreement with Illumina
Sequenta Enters into Agreement with Illumina to Commercialize In Vitro Diagnostic Kit
HTG Molecular Diagnostics Enters into Agreement with Illumina to Develop IVD Kits for Sequencing Tests
Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System
Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test
Pathogenica Enters Into Co-Marketing Agreement With Illumina
Oxford Nanopore To Terminate Co-Marketing Agreement With Illumina
Illumina Enters Into Co-Marketing Agreement With Hamilton Robotics
SynapDx Enters Into Co-Development Agreement With Illumina For Autism Diagnostic Tools
NextBio Enters Into Research Agreement With Emory University And Aflac Cancer Center For Medulloblastoma Biomarkers
NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers
Illumina Enters Into Technology Integration Agreement With Partners HealthCare System
Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center
Source BioScience Enters Into Co-Development Agreement With Barts Cancer Institute And Illumina
Olerup SSP Enters Into Distribution Agreement With Conexio Genomics
Covaris Enters Into Co-Marketing Agreement With Illumina
Desktop Genetics Raises Funds in Equity Investment
Illumina Raises USD550 Million in Private Placement of Notes Due 2019
Illumina Raises USD450 Million in Private Placement of 0.5% Notes Due 2021
Illumina Completes Private Placement Of 0.25% Convertible Senior Notes Due 2016 For US$800 Million
Human Longevity Acquires HiSeq X Ten Sequencing Systems From Illumina
Pathway Genomics Acquires MiSeqDx From Illumina
Novogene Acquires HiSeq X Ten Sequencing System From Illumina
Ambry Genetics Acquires HiSeq 2000 From Illumina
Illumina Acquires Conexio Genomics
Illumina Acquires GenoLogics Life Sciences
Illumina Acquires Myraqa, In-Vitro Diagnostics Company
Illumina Acquires NextBio, Clinical and Genomic Informatics Company
Illumina Completes Sale Of 13.5% Stake In Oxford Nanopore For US$91 Million
Illumina Acquires Advanced Liquid Logic
Illumina Completes Acquisition Of Verinata Health, In-Vitro Diagnostics Company, For Up To US$450 Million
Illumina Acquires Moleculo, Long-Read Sequencing Technology Developer
Roche Terminates Plans To Acquire Illumina
Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro Fertilization Screening Solutions
Illumina Acquires Epicentre Biotechnologies
Illumina Acquires Helixis
Illumina, Inc., Key Competitors
Illumina, Inc., Key Employees
Illumina, Inc., Other Locations
Illumina, Inc., Subsidiaries

LIST OF FIGURES

Illumina, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016
Illumina, Inc., Medical Equipment, Deals by Market, 2010 to YTD 2016
Skip to top


Ask Your Question

Illumina, Inc. (ILMN) - Medical Equipment - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: